food store for breast cancer patients, part 4

food store for breast cancer patients, part 4

food store for breast cancer patients

Conclusion
Governing bodies should consider health food stores as
commonly used, yet unregulated, sections of the health
care system. Educational interventions aimed at employees
might help to facilitate cooperation rather than stimulate
antagonism [12]. Education about safety and drug
interactions as well as regulations about the extent of
advice might best help to coordinate a move towards a
safer and more evidence-based health food business.
Concerned physicians and regulating bodies should be
aware of the variety of advice that breast cancer patients
receive about NHP use. Discussions about efficacy, safety
and cost should be initiated to be consistent with the
health beliefs and expectations of the patients and
providers.

Competing interests
None declared.

Acknowledgements
We thank Cinzia Genuardi, Laura Imola, Orest Szczurko, Andrea
Kenny, Stella Nonis, Tina Konstantinow, Camille Nghiem-Phu and
Sarah Dash-Arbuckle for participation in data gathering.

References
1. Berger E: Berger Population Health Monitor. Toronto: Hay Associates;
2002.
2. Alferi SM, Antoni MH, Ironson G, Kilbourn KM, Carver CS:
Factors predicting the use of complementary therapies in a
multi-ethnic sample of early-stage breast cancer patients. J
Am Med Womens Assoc 2001, 56:120-123.
3. Jonas WB: Alternative medicine – learning from the past,
examining the present, advancing to the future. JAMA 1998,
280:1616-1618.
4. US Food and Drug Administration: Risk of drug interactions
with St. John’s Wort. JAMA 2000, 283:1679.
5. Cassileth BR: Evaluating complementary and alternative therapies
for cancer patients. CA Cancer J Clin 1999, 49:362-375.
6. Ernst E, Cassileth BR: The prevalence of complementary/alternative
medicine in cancer: a systematic review. Cancer 1998,
83:777-782.
7. Morris KT, Johnson N, Homer L, Walts D: A comparison of complementary
therapy use between breast cancer patients and
patients with other primary tumor sites. Am J Surg 2000, 179:
407-411.
8. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A:
Effects of St. John’s wort on irinotecan metabolism. J Natl
Cancer Inst 2002, 94:1247-1249.
9. Spaulding-Albright N: A review of some herbal and related
products commonly used in cancer patients. J Am Diet Assoc
1997, 97:S208-S215.
10. Izzo AA, Ernst E: Interactions between herbal medicines and
prescribed drugs: a systematic review. Drugs 2001, 61:2163-
2175.
11. Adler SR, Fosket JR: Disclosing complementary and alternative
medicine use in the medical encounter: a qualitative study in
women with breast cancer. J Fam Pract 1999, 48:453-458.
12. Gotay CC, Dumitriu D: Health food store recommendations for
breast cancer patients. Arch Fam Med 2000, 9:692-699.
13. Stoffer S, Szpunar W, Coleman B, Mallos P: Advice from some
health food stores. JAMA 1980, 244:2044-2046.
14. Aigner C: Advice in healthfood stores. Nutr Forum 1998, 5:1-4.
15. Haidet JM: Poor advice plus doubletalk: a probe of ‘health
food’ stores in Central Ohio. Nutr Forum 1992, 9:6-9.
16. US Food and Drug Administration: Unsubstantiated Claims and
Documented Health Hazards in the Dietary Supplement Marketplace.
Rockville, Maryland: Food and Drug Administration; 1993.
17. Mills EJ, Singh R, Bast L, Kiani P, Hart J, Majlesi A, Kawasaki M,
Wilson K: Emerging issues associated with HIV patients
seeking advice from Health Food Stores. In International Scientific
Conference on Complementary, Alternative & Integrative
Medicine Research: April 13, 2002; Harvard Medical School,
Boston. Can J Pub Health 2003, in press.
18. Mills EJ, Singh R, Ross CP, Ernst E, Ray JG: Impact of Federal
Safety Advisories of health food store advice. CMAJ 2003, in
press.
19. Phillips LG, Nichols MH, King WD: Herbs and HIV: the health
food industry’s answer. South Med J 1995, 88:911-913.
20. Ernst E, Schmidt K: Health risks over the Internet: advice
offered by ‘medical herbalists’ to a pregnant woman. Wien
Med Wochenschr 2002, 152:190-192.
21. Geyer C, Hammond L, Johnson T, Smetzer L, Coyle J, Drengler R,
Von Hoff D, De Jager R, Rowinsky E: Dose-schedule optimization
the hexacyclic camptothecin (CPT) analog dx-8951f: a
phase I and pharmacokinetic study with escalation of both
treatment duration and dose [meeting abstract]. Proc Ann
Meet Am Soc Clin Oncol 1999, A813.
22. Lockwood K, Moesgaard S, Folkers K: Partial and complete
regression of breast cancer in patients in relation to dosage
of coenzyme Q10. Biochem Biophys Res Commun 1994, 199:
1504-1508.
23. Lockwood K, Moesgaard S, Yamamoto T, Folkers K: Progress on
therapy of breast cancer with vitamin Q10 and the regression
of metastases. Biochem Biophys Res Commun 1995, 212:172-
177.
24. Babu JR, Sundravel S, Arumugam G, Renuka R, Deepa N, Sachdanandam
P: Salubrious effect of vitamin C and vitamin E on
tamoxifen-treated women in breast cancer with reference to
plasma lipid and lipoprotein levels. Cancer Lett 2000, 151:1-5.
25. Kaegi E: Unconventional therapies for cancer: 1. Essiac. The
Task Force on Alternative Therapies of the Canadian Breast
Cancer Research Initiative. CMAJ 1998, 158:897-902.
26. Jain M, Miller AB: Tumor characteristics and survival of breast
cancer patients in relation to premorbid diet and body size.
Breast Cancer Res Treat 1997, 42:43-55.
27. Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D:
Phase I/II trial of the safety and efficacy of shark cartilage in
the treatment of advanced cancer. J Clin Oncol 1998, 16:
3649-3655.
28. Passalacqua R, Campione F, Caminiti C, Salvagni S, Barilli A,
Bella M, Barni S, Barsanti G, Caffo O, Carlini P, Cinquemani G, Di
Costanzo F, Giustini L, Labianca R, Mazzei A, Olmeo N,
Paccagnella A, Toscano L, Cocconi G: Patients’ opinions, feelings,
and attitudes after a campaign to promote the Di Bella
therapy. Lancet 1999, 353:1310-1314.
29. Montbriand MJ: Abandoning biomedicine for alternate therapies:
oncology patients’ stories. Cancer Nurs 1998, 21:36-45.
30. US Food and Drug Administration: Letter to Health Care Professionals
FDA Issues Consumer Advisory That Kava Products May
be Associated with Severe Liver Injury. Rockville, Maryland: US
Food and Drug Administration, Centre for Food Safety and
Applied Nutrition, Office of Nutritional Products, Labeling, and
Dietary Supplements; 2002.
31. Ernst E, Cohen MH: Informed consent in complementary and
alternative medicine. Arch Intern Med 2001, 161:2288-2292.